A new clinical study has demonstrated that nerandomilast, a novel treatment option, resulted in a significantly smaller decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis over a 52-week period when compared to placebo. The findings come from the FIBRONEER-ILD trial, a phase 3 study sponsored by Boehringer Ingelheim, registered under ClinicalTrials.gov number NCT05321082.
Progressive pulmonary fibrosis encompasses a group of interstitial lung diseases characterized by worsening respiratory symptoms, declining lung function, and increasing fibrosis over time. Among the standard measures of disease progression is forced vital capacity (FVC), a key indicator of lung performance.
The trial enrolled patients diagnosed with progressive forms of pulmonary fibrosis, including those with progressive fibrosing interstitial lung diseases (ILDs) not classified as idiopathic pulmonary fibrosis. Participants were randomly assigned to receive either nerandomilast or a placebo and were observed over a 52-week period. The primary outcome was the rate of decline in FVC, measured in milliliters.
Results from the study indicated that patients treated with nerandomilast experienced a slower decline in FVC compared to those receiving the placebo, suggesting that the drug may play a beneficial role in preserving lung function in affected patients.
These findings could represent a meaningful advancement in the treatment arsenal for progressive pulmonary fibrosis, which currently has limited therapeutic options. Boehringer Ingelheim, the sponsor of the trial, has indicated its commitment to further research and development in this area, with the hope of improving long-term outcomes for patients affected by the disease.
Source: https:// – Courtesy of the original publisher.
